Citation Impact
Citing Papers
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
2008
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
2011 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice
2012
Chemotherapy for small cell lung cancer
2003
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
2008
The biology and management of non-small cell lung cancer
2018 StandoutNature
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
2008
Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America
2002
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis
2003
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma
2004
Sensory Characteristics of Camphor
1990
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
1998
Lung Cancer
2008 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
What Cooks with Solar Neutrinos ?
1972 StandoutNatureNobel
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
1991
Coordinated regulation of myeloid cells by tumours
2012 Standout
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
2004
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Second line chemotherapy for NSCLC: establishing a gold standard
2002
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Lung cancer: current therapies and new targeted treatments
2016 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Global cancer statistics
2011 Standout
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
2008
A molecular signature of metastasis in primary solid tumors
2002 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis
2010 Standout
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
2001
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
2009
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases
2008
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
2004
MicroRNA signatures in human cancers
2006 Standout
Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer
2005
Microtubules as a target for anticancer drugs
2004 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Neutrophils in cancer: neutral no more
2016 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Small-cell lung cancer
2005
HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome
2004
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Platinum drugs in the treatment of non-small-cell lung cancer
2002
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain
2008 StandoutNobel
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
2004
Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma
2012
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Spectrochemical characterization by micro-FTIR spectroscopy of blue pigments in different polychrome works of art
1999
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
Chemotherapy of advanced non-small cell lung cancer
1999
Cancer statistics in China, 2015
2016 Standout
Impaired Thermosensation in Mice Lacking TRPV3, a Heat and Camphor Sensor in the Skin
2005 StandoutScienceNobel
Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome
2008
Réactions (p, 2p) À 156 MeV
1967
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2000
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
A Decade of Raman Spectroscopy in Art and Archaeology
2007 Standout
TRP ION CHANNELS AND TEMPERATURE SENSATION
2006 StandoutNobel
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
Global cancer statistics, 2012
2015 Standout
Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma
2009
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of J. Lecomte being referenced
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party
2007
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
1996
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1998
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
1989
Prognostic factors for patients with small cell lung carcinoma
2000
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)
1996
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
2007
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
2001
Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy
2004
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer
1999
II. — Détermination expérimentale et essai d'attribution des vibrations actives en infrarouge de quelques carbonates basiques métalliques à l'état cristallin
1970
Note de l'éditeur
1966
[The common chemical sense].
1963
A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC)
2006